



IAPS Rec'd PCT/PTO 23 JUN 2006

PATENT
ATTORNEY DOCKET NO. 00786/424003

Certificate of Mailing: Date of Deposit: June 21, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kathy Kirby

Printed name of person mailing correspondence

Kathy Kirby
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Rakesh K. Jain et al.

Confirmation No.: 5667

Serial No.: 10/507,352

Art Unit: 1642

Filed: September 10, 2004

Examiner: Peter J. Redding

Customer No.: 21559

Title: USE OF SIGNAL TRANSDUCTION INHIBITORS AND
COMBINATION THERAPIES FOR THE PREVENTION OR
TREATMENT OF CANCER AND ANGIOGENESIS RELATED
DISEASES

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made,


material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 21 June 2006



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	00786/424003
		Serial No.	10/507,352
		Applicant	Jain, Rakesh, K. <i>et al.</i>
		Filing Date	September 10, 2004
		Group	1642
		IDS Filed	June 21, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	6,165,464	December 26, 2000	Hudziak et al.			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Bornstein, "Thrombospondins as Matricellular Modulators of Cell Function," <i>J. Clin. Invest.</i> 107: 929-934 (2001).					
	Carmeliet et al., "Angiogenesis in Cancer and Other Diseases," <i>Nature</i> 407: 249-257 (2000).					
	Harkin, "Uncovering Functionally Relevant Signaling Pathways Using Microarray-Based Expression Profiling," <i>The Oncologist</i> 5: 501-507 (2000).					
	Izumi et al., "Herceptin Acts as an Anti-Angiogenic Cocktail," <i>Nature</i> 416: 279-280 (2002).					
	Jain et al., "Transparent Window Models and Intravital Microscopy: Imaging Gene Expression, Physiological Function and Drug Delivery in Tumors," <i>In: Tumor Models in Cancer Research</i> , B. Teicher, Ed., Humana Press, Inc., Totowa, NJ, Chapter 34: 647-671 (2001)					
	Kerbel et al., "'Accidental' Anti-angiogenic Drugs: Anti-Oncogene Directed Signal Transduction Inhibitors and Conventional Chemotherapeutic Agents as Examples," <i>Eur. J. Cancer</i> 36:1248-1257 (2000).					
	Marrack et al., "Genomic-scale Analysis of Gene Expression in Resting and Activated T Cells," <i>Curr. Opin. Immunol.</i> 12: 206-209 (2000).					
	Normanno et al., "Synergistic Growth Inhibition and Induction of Apoptosis by a Novel Mixed Backbone Antisense Oligonucleotide Targeting CRIPTO in Combination with C225 and Anti-EGFR Monoclonal Antibody and 8-C1-cAMP in Human GEO Colon Cancer Cells," <i>Oncol. Rep.</i> 6:1105-1109 (1999).					
	Pelizzari et al., "Quantitative Analysis of DNA Array Autoradiographs," <i>Nucleic Acids Res.</i> 28: 4577-4581 (2000).					
	Slamon et al., "Use of Chemotherapy Plus a Monoclonal Antibody Against HER2 for Metastatic Breast Cancer That Overexpresses HER2," <i>N. Engl. J. Med.</i> 344: 783-792 (2001).					
	Thurston et al., "Leakage-resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1," <i>Science</i> 286: 2511-2514 (1999).					
	Yarden et al., "Untangling the ErbB Signalling Network," <i>Nat. Rev. Mol. Cell Biol.</i> 2: 127-137 (2001).					
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						

<p>SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> <p>(37 C.F.R. § 1.98(b))</p>	<p>Attorney Docket No. 00786/424003</p> <p>Serial No. 10/507,352</p> <p>Applicant Jain, Rakesh, K. <i>et al.</i></p> <p>Filing Date September 10, 2004</p> <p>Group 1642</p> <p>IDS Filed June 21, 2006</p>
--	---

	International Search Report Application No. PCT/US03/06796

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	